OncoMatch/Clinical Trials/NCT06208371
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
Is NCT06208371 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Palliative Chemotherapy for colorectal neoplasms malignant.
Treatment: Palliative Chemotherapy — The goal of this clinical trial is to investigate the effectiveness of localized interventions in improving the 5-year survival rate for colorectal cancer patients with ≥10 liver metastases. We aim to answer the following question: Can localized interventions, including surgery and/or ablation and/or stereotactic body radiotherapy (SBRT), enhance the 5-year survival rate compared to palliative chemotherapy alone in patients with ≥10 colorectal liver metastases (CRLM)? Participants in this study, who have achieved disease control through chemotherapy, will undergo either localized interventions (surgery and/or ablation and/or SBRT) or receive palliative chemotherapy alone. Researchers will compare the survival outcomes between these groups to determine the potential benefits of localized interventions for patients with ≥10 CRLM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic chemotherapy
Disease control (PR or SD) achieved after a minimum of 8 cycles of systemic chemotherapy
Lab requirements
Blood counts
normal hematological function at baseline
Kidney function
normal renal function at baseline
Liver function
Child-Pugh grade A liver function; normal hepatic function at baseline
Normal hematological, hepatic, and renal functions at baseline. Child-Pugh grade A liver function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify